• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

Research

19 September 2022 RaaS Advisory: Targeting treatment for autism spectrum disorder
20 July 2022 Bioshares – Edition 921: Neurotech International – Positive Study Results
3 June 2022 Bioshares – Edition 918: Neurotech International – Efficacy Results Pending

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1679485521anoit1679485521anret1679485521nihce1679485521torue1679485521n@ofn1679485521i1679485521

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus